ABLIVA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1598 SEK | -0.12% |
|
-1.36% | -34.91% |
| Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Calendar
2024-05-20
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.91% | 19.75M | |
| -3.32% | 104B | |
| +0.05% | 97.42B | |
| +1.46% | 22.2B | |
| -18.28% | 21.23B | |
| -10.72% | 18.33B | |
| -42.33% | 16.35B | |
| -17.29% | 15.06B | |
| +3.57% | 13.98B | |
| +27.78% | 11.66B |
- Stock Market
- Equities
- ABLI Stock
- News Abliva AB
- Abliva Starts Mid-stage Study Of Rare Metabolical Disease Drug
